Biomedicines, Vol. 11, Pages 919: Immunization with Neural-Derived Peptides in Neurodegenerative Diseases: A Narrative Review

Biomedicines, Vol. 11, Pages 919: Immunization with Neural-Derived Peptides in Neurodegenerative Diseases: A Narrative Review

Biomedicines doi: 10.3390/biomedicines11030919

Authors: Germán Rivera Monroy Renata Murguiondo Pérez Efraín Weintraub Ben Zión Oscar Vidal Alcántar-Garibay Ericka Cristina Loza-López Emilio Tejerina Marion Enrique Blancarte Hernández Lisset Navarro-Torres Antonio Ibarra

Neurodegenerative diseases (NDDs) are a major health problem worldwide. Statistics suggest that in America in 2030 there will be more than 12 million people suffering from a neurodegenerative pathology. Furthermore, the increase in life expectancy enhances the importance of finding new and better therapies for these pathologies. NDDs could be classified into chronic or acute, depending on the time required for the development of clinical symptoms and brain degeneration. Nevertheless, both chronic and acute stages share a common immune and inflammatory pathway in their pathophysiology. Immunization with neural-derived peptides (INDP) is a novel therapy that has been studied during the last decade. By inoculating neural-derived peptides obtained from the central nervous system (CNS), this therapy aims to boost protective autoimmunity, an autoreactive response that leads to a protective phenotype that produces a healing environment and neuroregeneration instead of causing damage. INDP has shown promising findings in studies performed either in vitro, in vivo or even in some pre-clinical trials of different NDDs, standing as a potentially beneficial therapy. In this review, we will describe some of the studies in which the effect of INDP strategies have been explored in different (chronic and acute) neurodegenerative diseases.